AbbVie Inc. ROE

ROE of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2019 was 0.0% (a -100.0% decrease from previous year)
  • Annual ROE for 2018 was -339.62% (a -411.32% decrease from previous year)
  • Annual ROE for 2017 was 109.09% (a -21.38% decrease from previous year)
  • Twelve month ROE ending December 30, 2019 was 0.0% (a -100.0% decrease compared to previous quarter)
  • Twelve month trailing ROE decreased by -100.0% year-over-year
Trailing ROE for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
0.0% -58.4% -68.97% -250.88%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of AbbVie Inc.

Most recent ROEof ABBV including historical data for past 10 years.

Interactive Chart of ROE of AbbVie Inc.

AbbVie Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 0.0%
2018 -339.62%
2017 109.09%
2016 138.75%
2015 180.9%
2014 56.91%
2013 105.11%
2012 68.98%
2011 24.85%
2010 0.0%
2009 0.0%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.